-
AEON Biopharma holds FDA meeting, gets shareholder approval for financing
-
AEON Biopharma signs debt exchange deal with Daewoong
-
AEON Biopharma (AEON) Misses Q3 EPS by 39c
-
AEON Biopharma reports ABP-450 biosimilar data ahead of FDA meeting
-
AEON Biopharma (AEON) Announces NYSE American Acceptance of Plan to Regain Listing Compliance
-
AEON Biopharma (AEON) Appoints Rob Bancroft as CEO
-
AEON Biopharma (AEON) Announces CEO Change
-
AEON Biopharma (AEON) Announces 1:72 Reverse Share Split
-
AEON Biopharma (AEON) Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
-
AEON Biopharma (AEON) Prices 40M Unit Offering at $0.50/unit
-
H.C. Wainwright Reiterates Buy Rating on AEON Biopharma, Inc (AEON)
-
AEON Biopharma (AEON) Announces Positive Outcome from FDA Biosimilar Advisory Meeting
-
AEON Biopharma (AEON) Files $200M Mixed Shelf
-
AEON Biopharma, Inc (AEON) PT Lowered to $5 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on AEON Biopharma, Inc (AEON)

